Panelists discuss how the CARTITUDE-4 clinical trial demonstrated that ciltacabtagene autoleucel (cilta-cel) chimeric antigen receptor (CAR) T-cell therapy significantly outperformed standard-of-care treatments in patients with early relapsed/refractory multiple myeloma (R/R MM), showing higher response rates, complete remission rates, and deeper minimal residual disease (MRD)-negative remissions while also providing superior quality of life with treatment breaks vs continuous therapy requirements, and, most importantly, becoming the first therapy in this patient population to demonstrate improved overall survival and actually prolong life.